Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Canada's Valeant Pharmaceuticals International (TSX: VRX) has entered into an agreement to acquire Dermik, a dermatology unit of French drug major Sanofi (Euronext: SAN)) in the USA and Canada, as well as the worldwide rights to Sculptra Aesthetic (injectable poly-L-lactic acid). 11 July 2011
Pharmaceutical
Spain's largest pharmaceutical firm, Almirall (ALM: MC) yesterday announced the German launch of cannabis-based drug Sativex for the treatment of spasticity in multiple sclerosis (MS) and the approval of Actikerall (LAS1005) for the treatment of hyperkeratotic actinic keratosis (grade I/II) in adult patients, which will be launched on July 15. 6 July 2011
Pharmaceutical
The USA's biopharmaceutical research companies currently are developing 277 medicines to help the more than 100 million Americans, one third of the US population, who suffer from at least one skin disease. 15 June 2011
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year collaboration with fellow UK-based drug developer Heptares Therapeutics focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). 31 May 2011
Generics
SOHM (PINKSHEETS: SHMN), a USA-based import/export organization specializing in global trading in generic drugs in emerging markets, says that it has signed a letter of intent (LOI) to acquire a high-growth dermatology company based in India. It did not reveal the name of the firm, nor the cost of the acquisition. 11 April 2011
Pharmaceutical
Swiss drug major Novartis(NOVN: VX) has signed an agreement to sell to Swedish drugmaker Meda AB (MEDA: SS) the global rights to manufacture, market and commercialize Elidel (pimecrolimus) cream 1%, a treatment for mild to moderate atopic dermatitis. This agreement reflects Novartis strategy to focus commercialization on new launch portfolio and core brands, the company said. 7 April 2011
Pharmaceutical
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, an autoimmune disease that affects the blood vessels and connective tissue, according to results from an open-label Phase II trial. 29 March 2011
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Switzerland's Galderma Pharma have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide. 8 March 2011
Pharmaceutical
Shares of UK-based biopharmaceutical firm Renovo (LSE: RNVO) plunged 75.1% to 17 pence last Friday, after the company announced that its first European Union Phase III trial for Juvista (avotermin), in scar revision surgery (REVISE) did not meet its primary or secondary endpoints. Renovo says it will conduct further exploratory analysis and determine the future of the Juvista development program. 14 February 2011
Pharmaceutical
Canada's Valeant Pharmaceuticals International (TSX: VRX) went on another shopping spree yesterday, with its subsidiary, Biovail Laboratories International acquiring the Canadian rights to Cholestagel (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, from Genzyme, which will receive a $2 million upfront payment from Biovail, to be followed by subsequent additional milestone payments totaling up to $7 million. 11 February 2011
Pharmaceutical
US companies Medicis Pharmaceutical (NYSE:MRX) and Anacor Pharmaceuticals (Nasdaq: ANAC) have entered into an R&D agreement to discover and develop boron-based small-molecule compounds directed against a target for the potential treatment of acne. 11 February 2011
Biotechnology
The European Medicines Agency says it has been formally notified by US Health care major Abbott Laboratories (NYSE: ABT) of its decision to withdraw its application for a centralized marketing authorization for Ozespa (briakinumab), 100mg solution for injection. The drug's Biological License Application has also been withdrawn in the USA, Abbott said in a separate US Securities and Exchange Commission filing. 18 January 2011
Pharmaceutical
London, UK-based Sinclair Pharma (LSE: SPH) saw its shares leap 19.7% to 39.25 pence on Tuesday, after the company announced a long-term partnership for the commercialization of its market leading brands in Asia Pacific with Singapore-headquartered Invida Holdings. The stock rose further yesterday on a second deal announcement with Sunstar, giving the UK firm a market capitalization of about 90 million ($141.5 million). 9 December 2010
Pharmaceutical
Hyderabad-based Dr Reddy's Laboratories (DRL; NYSE: RDY), India's second largest drugmaker, has entered into an agreement with fellow Indian firm Cipla (NSE: CIPLA; BSE 500087) for exclusive marketing rights to a portfolio of prescription drugs and over-the-counter medicines in the Russian and Ukraine markets. 26 October 2010
Pharmaceutical
German drugmaker Bayer HealthCare's (BAY. DE) dermatology business Intendis has entered an agreement with USA-based KYTHERA Biopharmaceuticals to develop and commercialize ATX-101; an adipolytic agent designed to reduce small volumes of facial fat through aesthetics' applications. 31 August 2010
Pharmaceutical
Agreeing to open up its drug safety files for the first time, the European Medicines Agency (EMEA) has said that it will release documents related to a drug used to treat severe forms of acne. This is with respect to a complainant, an Irish citizen, who had asked for the release of reports concerning suspected adverse reactions to the drug and, earlier this year, European Ombudsman P Nikiforos Diamandouros told the Agency to reconsider its policy (The Pharma Letter May 12). 12 August 2010
Biotechnology
The continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors, along with a twofold increase in the penetration of biologics in the moderate-to-severe population, will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to advisory firm Decision Resources. 10 August 2010
Generics
Matrix Laboratories, a unit of US generics major Mylan, has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for minocycline hydrochloride extended release tablets, 45mg, 90mg and 135mg, the generic version of Solodyn ER, a treatment for acne, sold by Medicis Pharmaceuticals. Group company Mylan Pharmaceuticals commenced immediate shipment of the product after approval. 26 July 2010
Pharmaceutical
US RNAi-based drug development firm RXi Pharmaceuticals has announced the company's new focused RNAi therapeutic strategy at the Jefferies 2010 Global Life Sciences Conference. 14 June 2010
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze